Compare prices and buy ARA-290 from 25 research peptide vendors - also called suppliers or sources. Updated daily.
Cibinetide (ARA-290, CAS 1208243-50-8) is an 11-amino-acid synthetic peptide, pGlu-EQLERALNSS, designed by Brines, Cerami and colleagues to mimic the outward-facing surface of erythropoietin's helix B. It was not erythropoietic in cell or rat assays. Its developers attribute its effects to a proposed complex of the EPO receptor and the beta-common receptor, a model other laboratories dispute. Small Phase 2 trials have tested it in sarcoidosis and type 2 diabetes. Not FDA-approved.
For research purposes only. Not medical advice.
ARA-290, international nonproprietary name cibinetide, is an 11-amino-acid synthetic peptide with the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser and the formula C51H84N16O21. Its first residue is pyroglutamate, so research papers also call it pHBSP, for pyroglutamate helix B surface peptide.
Michael Brines, Anthony Cerami and colleagues, then at Warren Pharmaceuticals in Ossining, New York, described it in PNAS in 2008. They took the amino acids that face outward along helix B of erythropoietin (EPO), added three from the adjoining loop, and joined them into one chain. The paper calls the result unrelated to EPO in primary sequence, a mimic of the folded hormone's surface and not a segment of its chain. It was not erythropoietic in a cell assay or in rats. Its trials were run by Araim Pharmaceuticals, which listed Brines and Cerami as officers, or by academic groups working with the company.
Its developers attribute EPO's tissue-protective effects to a receptor separate from the one that drives red-cell production, a complex of the EPO receptor and the beta-common receptor (CD131) proposed in 2004 (Brines et al., PNAS) and later named the innate repair receptor. In their mouse work, ARA-290 reduced allodynia after nerve injury in wild-type mice and had no effect in mice lacking the beta-common receptor (Swartjes et al., Anesthesiology, 2011).
Other laboratories dispute the model. Amgen scientists reported functional EPO receptor undetectable in endothelial, cardiac, neuronal and renal cells (Sinclair et al., Blood, 2010). A 2018 biophysical study found that the extracellular regions of the two receptors do not specifically associate in vitro, with or without ARA-290 (Cheung Tung Shing et al., Scientific Reports).
The preclinical record spans animal models of nerve, kidney, heart and wound injury. Two of those papers have been retracted: a rat kidney-injury study (Molecular Medicine, 2012), retracted in February 2026 over blots the publisher found unrepresentative of the results, and a mouse insulin-resistance study (British Journal of Pharmacology, 2014), retracted in 2024.
The human evidence comes from small trials with treatment periods of four to twelve weeks, and each patient trial below lists Araim officers or employees among its authors.
As of October 2026, ClinicalTrials.gov lists no Phase 3 study of the compound.
Cibinetide holds no FDA approval, and no approved drug contains it. FDA's orphan drug database lists four designations granted to Araim between 2009 and 2016, covering sarcoidosis, neuropathic pain in sarcoidosis, delayed graft function after kidney transplant and pancreatic islet transplantation. Orphan designation qualifies a sponsor for development incentives and is separate from approval.
The compound appears in neither table of FDA's Category 2 page for bulk drug substances that may present significant safety risks in compounding (April 22, 2026 revision), and the 503A bulks list at 21 CFR 216.23 does not name it.
The World Anti-Doping Agency's Prohibited List does not name ARA-290. Section S2.1.5 bans innate repair receptor agonists, the class its developers place it in, citing asialo EPO and carbamylated EPO, and S2 extends to substances with a similar biological effect. Anti-doping researchers have published a urine screening method that detects ARA-290 (Thomas et al., Journal of Separation Science, 2016). The site's 2027 Prohibited List summary explains how the S2 and S0 classes work.
Vendors list it as ARA-290, ARA 290 or cibinetide, often together, as in "ARA-290 (Cibinetide)," and at least one storefront spells it "Cibinitide." Listings are vials. PeptideScouter indexes it per milligram and verifies identity against the molecular formula rather than the product title.
No. ARA-290 is an 11-amino-acid synthetic peptide built to imitate one outward-facing surface of erythropoietin, and the 2008 PNAS paper that introduced it describes it as unrelated to erythropoietin in primary sequence. In that paper it was not erythropoietic in a cell assay or in rats. In a four-week placebo-controlled trial in 22 patients with sarcoidosis, hemoglobin did not differ between groups and stood at 8.7 mmol/L in both at the end of dosing.
Cibinetide is the international nonproprietary name for ARA-290, and the two names refer to the same molecule. It is an 11-residue peptide with the sequence pyroglutamate-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser and the formula C51H84N16O21, which research papers also call pyroglutamate helix B surface peptide, or pHBSP. It was described in 2008 by Michael Brines, Anthony Cerami and colleagues, and its clinical trials were run by Araim Pharmaceuticals or by academic groups working with the company. Some vendors misspell the name as Cibinitide.
Yes, in small trials with treatment periods of four to twelve weeks. Two placebo-controlled studies in sarcoidosis patients with small-fiber neuropathy symptoms, with 22 and 38 patients, reported larger improvements on a neuropathy symptom questionnaire than placebo. A 64-patient Phase 2b trial found a significant increase in corneal nerve fiber area at only the middle of three dose levels, and pain improved in all groups including placebo. A 49-patient study in type 2 diabetes with painful neuropathy reported a small HbA1c reduction against placebo, and a nine-patient open-label study in diabetic macular edema found no improvement in visual acuity or retinal thickness. As of October 2026, ClinicalTrials.gov lists no Phase 3 study.
No. Cibinetide holds no FDA approval and is not a component of any approved drug. FDA has granted Araim Pharmaceuticals four orphan drug designations for it, covering sarcoidosis, neuropathic pain in sarcoidosis, delayed graft function after kidney transplant and pancreatic islet transplantation. Orphan designation qualifies a sponsor for development incentives and is a separate process from approval, and FDA's database lists all four indications as not approved. ARA-290 does not appear in either table of FDA's Category 2 list of bulk drug substances for compounding. Material sold by research vendors is offered for laboratory research only, not for human consumption.
The World Anti-Doping Agency's Prohibited List does not name ARA-290 or cibinetide. Its section S2.1.5 prohibits innate repair receptor agonists at all times, giving asialo EPO and carbamylated EPO as examples, and section S2 also covers other substances with a similar chemical structure or biological effect. ARA-290's developers describe it as an innate repair receptor agonist. Anti-doping researchers published a urine screening method that detects ARA-290 in 2016 and an in vitro map of its breakdown products in blood samples in 2017.
ARA-290 is sold by 25 research peptide vendors indexed on PeptideScouter, with 37 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
24 of the 25 indexed vendors currently have ARA-290 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists ARA-290 at $2.50/mg, the lowest listed price across 25 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.25/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 25 vendors listing ARA-290 publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.50/mg listed to $2.25/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
ARA-290 ranges from $2.50/mg to $8.00/mg across 37 listings from 25 research peptide vendors, normalized to USD per milligram and refreshed daily.
25 research peptide vendors currently list ARA-290 on PeptideScouter, with 24 in stock right now. We track 37 listings across size and kit variants.
ARA-290's CAS Registry Number is 1208243-50-8. It is also sold as ARA-290 (Cibinetide), Cibinetide, Cibinitide ARA-290.
